63 related articles for article (PubMed ID: 20545800)
1. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis.
McIntyre RS; Cragin L; Sorensen S; Naci H; Baker T; Roussy JP
J Eval Clin Pract; 2010 Aug; 16(4):744-55. PubMed ID: 20545800
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
Obradovic M; Mrhar A; Kos M
Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
[TBL] [Abstract][Full Text] [Related]
3. The CATIE schizophrenia trial: results, impact, controversy.
Manschreck TC; Boshes RA
Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
[TBL] [Abstract][Full Text] [Related]
4. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in the long-term treatment and the role of second-generation antipsychotics.
Mohr P
Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():117-33. PubMed ID: 17262004
[TBL] [Abstract][Full Text] [Related]
6. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
Motlová L; Spaniel F; Höschl C; Balon R
Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
[TBL] [Abstract][Full Text] [Related]
7. Selection of atypical antipsychotics for the management of schizophrenia.
Sprague DA; Loewen PS; Raymond CB
Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).
Bernardo M; Azanza JR; Rubio-Terrés C; Rejas J
Actas Esp Psiquiatr; 2007; 35(4):259-62. PubMed ID: 17592789
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of long-acting risperidone in Sweden.
Hensen M; Heeg B; Löthgren M; van Hout B
Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
[TBL] [Abstract][Full Text] [Related]
10. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
Nasrallah HA
J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
[TBL] [Abstract][Full Text] [Related]
11. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis.
Lin L; Zhao YJ; Zhou HJ; Khoo AL; Teng M; Soh LB; Lim BP; Sim K
Int Clin Psychopharmacol; 2016 Mar; 31(2):84-92. PubMed ID: 26619182
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and Price of Aripiprazole for Schizophrenia in the Brazilian Public Health System.
Soares Santos A; de Souza Noronha KVM; Viegas Andrade M; Mariano Ruas C
J Ment Health Policy Econ; 2020 Mar; 23(1):27-37. PubMed ID: 32458815
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.
Lachaine J; Beauchemin C; Mathurin K; Gilbert D; Beillat M
J Med Econ; 2014 Apr; 17(4):296-304. PubMed ID: 24564402
[TBL] [Abstract][Full Text] [Related]
14. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs.
Darbà J; Kaskens L; Aranda P; Arango C; Bobes J; Carmena R; Rejas J
Ann Clin Psychiatry; 2013 Feb; 25(1):17-26. PubMed ID: 23376866
[TBL] [Abstract][Full Text] [Related]
15. Practical applications of recent antipsychotic effectiveness data.
J Clin Psychiatry; 2007 Jan; 68(1):151-62. PubMed ID: 17284143
[No Abstract] [Full Text] [Related]
16. Cataract occurrence with antipsychotic drugs.
Shahzad S; Suleman MI; Shahab H; Mazour I; Kaur A; Rudzinskiy P; Lippmann S
Psychosomatics; 2002; 43(5):354-9. PubMed ID: 12297603
[TBL] [Abstract][Full Text] [Related]
17. The revised DGPPN and APA schizophrenia guidelines: Guideline quality and recommendations for long-term antipsychotic treatment.
Gaebel W; Stricker J; Hasan A; Falkai P; McIntyre JS; Kerst A
Schizophr Res; 2021 Mar; 229():137-139. PubMed ID: 33203610
[No Abstract] [Full Text] [Related]
18. Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone.
Carpenter WT
Evid Based Ment Health; 2006 Nov; 9(4):106. PubMed ID: 17065303
[No Abstract] [Full Text] [Related]
19. The functional sequelae of schizophrenia: consequences of long-term pharmacotherapy and the neurobiology of addiction.
Falkai P; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2011 Mar; 261(2):83-4. PubMed ID: 21328016
[No Abstract] [Full Text] [Related]
20. Bridging the Efficacy-Effectiveness Gap in the Antipsychotic Treatment of Schizophrenia: Back to the Basics.
Ramesh B; Tandon R
Asian J Psychiatr; 2019 Feb; 40():A1-A2. PubMed ID: 30928014
[No Abstract] [Full Text] [Related]
[Next] [New Search]
